Zola
1
50M
1
0.12
1
- Areas of investment
Summary
Zola appeared to be the Corporate Investor, which was created in 2013. The leading representative office of defined Corporate Investor is situated in the New York. The venture was found in North America in United States.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Zola, startups are often financed by Rahul Mehta, Nimble Ventures, LIAN Group. The meaningful sponsors for the fund in investment in the same round are Olive Tree Capital, Jackson Square Ventures, Greenoaks Capital. In the next rounds fund is usually obtained by DNA Capital.
The high activity for fund was in 2018. The fund is generally included in less than 2 deals every year. The common things for fund are deals in the range of 50 - 100 millions dollars.
This organization was formed by Felix Lung, Kevin Ryan, Nobu Nakaguchi, Shan-Lyn Ma.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Alto Pharmacy Among the most successful fund investment fields, there are Software, Consumer Software. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 1
- Rounds per year
- 0.12
- Investments by industry
- E-Commerce (1)
- Consumer (1)
- Pharmaceutical (1)
- Health Care (1)
- Medical (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Avg. valuation at time of investment
- 750M
- Group Appearance index
- 1.00
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Alto Pharmacy | 05 Dec 2018 | E-Commerce, Consumer, Health Care, Medical, Pharmaceutical | Late Stage Venture | 50M | United States, California, San Francisco |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.